ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Anti-miRNA- 155 - 5p enhances the cytotoxic efficacy of temozolomide in brain cancer stem cells.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to assess the molecular effects of the miR- 155 - 5p in modulating Temozolomide chemosensitivity, which was examined utilizing in silico and in vitro methods on brain cancer stem cells (BCSCs) that exhibit high differentiation, apoptosis avoidance, and a remarkable capacity for self-renewal as a mechanism of chemotherapeutic resistance. The hypothesis of the study is how miR- 155 - 5p modulates temozolomide chemosensitivity in brain cancer stem cells (BCSCs) and their differentiated counterparts (BSCs) and whether it influences the molecular mechanisms underlying tumour recurrence and treatment failure. By silencing miR- 155 - 5p using anti-miR oligonucleotides, the knockdown efficiency of miR- 155 - 5p was confirmed via quantitative qRT-PCR. The increased chemosensitivity effect of miR- 155 - 5p against temozolomide in BCSCs and BCSs was measured by cytotoxicity assay. Subsequently, all studied groups were evaluated by performing cell viability, cell cycle, and apoptosis tests. miRNA-mRNA-pathway interactions were analyzed using different bioinformatics tools and databases. Cell viability was significantly reduced by 42.9% in the combined treatment (anti-miR- 155 - 5p + temozolomide) group compared to the untreated group. Temozolomide treatment in combination with anti-miR- 155 - 5p showed a significant decrease in cell viability compared to temozolomide alone. In contrast, late apoptosis increased 2.10-fold (p < 0.0001), indicating a synergistic effect in promoting late apoptosis. Combining temozolomide and anti-miR- 155 - 5p inhibits DNA synthesis by causing G2 phase arrest. mRNAs targeted by miR- 155 - 5p and significantly down-regulated in glioblastoma included GABRA1, GABRB2, SCN1A, GRIN2A, and SGIP1. By survival analysis, low expression of SCN1A was associated with poor prognosis (p < 0.05; HR = 0.7), highlighting its potential prognostic role. The combination of temozolomide treatment with suppression of miR- 155 - 5p may provide a more effective and side-effect minimized brain cancer treatment strategy by reducing resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.